About
Dr. Mark Gelbert brings more than three decades in consumer healthcare as a leader in Rx-to-OTC switch and FDA regulatory policy — the rigor behind everything we build.
With a Ph.D. in chemistry and a law degree, Dr. Gelbert has held senior scientific-affairs roles at Procter & Gamble, Sandoz, Novartis, Schering-Plough, Pfizer, Johnson & Johnson, and Nature’s Bounty — overseeing the approval of hundreds of OTC products behind iconic brands including Pepto-Bismol, Claritin, Benadryl, Nicorette, Rogaine, and Advil.
He led landmark Rx-to-OTC switches — among them Lamisil, Lotrimin Ultra, Claritin, Zantac 150, Zyrtec, and Nexium 24HR — and helped establish the label-comprehension and actual-use study methods the industry relies on today. A contributor to the Consumer Healthcare Products Association (CHPA) for nearly 25 years, he advises Let There Be on regulatory strategy and scientific rigor.
Let's build something worth believing.
Bring us your science — we'll bring the team that knows what to do with it.
Start the conversation